MCWF (Amplimune) Offers an Alternative for Herd Health as FDA Further Restricts Antibiotics
Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.
MCWF (Amplimune) Significantly Improves Fertility and Decreases Clinical Mastitis and Metritis in Organic-Certified Dairy Herd
In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.
NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.
MCWF Greatly Improves Pregnancy Success in Heifer Embryo Transfer Recipients
An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.
Amplimune® Receives Regulatory Approval in New Zealand
NovaVive's immunotherapy for calf scours - Amplimune® - has received approval for sale in New Zealand by Agricultural Compounds and Veterinary Medicines (ACVM). NovaVive has appointed Agilis Vet Ltd as its NZ distributor.
Amplimune® Administered in Calves Prior to Shipment Shows Economic Benefit
Data from a University of Minnesota research study presented by Dr. Luciano Caixeta at the AABP annual conference in St. Louis, MO last week shows an economic benefit to the use of Amplimune in calves prior to shipping.